Relmada Therapeutics, Inc.
RLMD
$4.07
$0.030.74%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.29M | 7.40M | 6.27M | 8.08M | 11.86M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.33M | 10.22M | 18.22M | 19.08M | 23.01M |
| Operating Income | -10.33M | -10.22M | -18.22M | -19.08M | -23.01M |
| Income Before Tax | -10.09M | -9.87M | -17.56M | -18.66M | -21.73M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.09M | -9.87M | -17.56M | -18.66M | -21.73M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.09M | -9.87M | -17.56M | -18.66M | -21.73M |
| EBIT | -10.33M | -10.22M | -18.22M | -19.08M | -23.01M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.30 | -0.30 | -0.58 | -0.62 | -0.72 |
| Normalized Basic EPS | -0.19 | -0.19 | -0.37 | -0.38 | -0.46 |
| EPS Diluted | -0.30 | -0.30 | -0.58 | -0.62 | -0.72 |
| Normalized Diluted EPS | -0.19 | -0.19 | -0.37 | -0.38 | -0.46 |
| Average Basic Shares Outstanding | 33.19M | 33.19M | 30.41M | 30.17M | 30.17M |
| Average Diluted Shares Outstanding | 33.19M | 33.19M | 30.41M | 30.17M | 30.17M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |